

Review of: "Targeting Alzheimer's disease hallmarks with the Nrf2 activator Isoeugenol"

Giuseppe Uras¹

¹ University College London, University of London

Potential competing interests: No potential competing interests to declare.

The work by Ana Silva and Sonia Silva aims to target 3 fundamental aspects of Alzheimer's disease: neuroinflammation, oxidative stress, and accumulation of amyloid peptides. In order to reduce such toxic hallmarks, the authors activate the Nrf2 pathway via Isoeugenol treatment. In the work described here, they have shown good pharmacokinetics and pharmacodynamics. Their conclusions are well supported by the results described here. I would address a bit more the Tau role, and its potential via GSK3-beta phosphorylation. I suggest this reading [10.3390/ijms232314794](https://doi.org/10.3390/ijms232314794).